Changes in the Synaptic Proteome in Tauopathy and Rescue of Tau-Induced Synapse Loss by C1q Antibodies


Authors: B. Dejanovic, M.A. Huntley, A. De Mazière, W.J. Meilandt, T. Wu, K. Srinivasan and M. Sheng et al.

Journal: Neuron

DOI: 10.1016/j.neuron.2018.10.014

Publication - Abstract

November 01, 2018

Neuroscience Nucleic Acid Lipid Nanoparticles siRNA
Synapse loss and Tau pathology are hallmarks of Alzheimer’s disease (AD) and other tauopathies, but how Tau pathology causes synapse loss is unclear. We used unbiased proteomic analysis of postsynaptic densities (PSDs) in Tau-P301S transgenic mice to identify Tau-dependent alterations in synapses prior to overt neurodegeneration. Multiple proteins and pathways were altered in Tau-P301S PSDs, including depletion of a set of GTPase-regulatory proteins that leads to actin cytoskeletal defects and loss of dendritic spines. Furthermore, we found striking accumulation of complement C1q in the PSDs of Tau-P301S mice and AD patients. At synapses, C1q decorated perisynaptic membranes, accumulated in correlation with phospho-Tau, and was associated with augmented microglial engulfment of synapses and decline of synapse density. A C1q-blocking antibody inhibited microglial synapse removal in cultured neurons and in Tau-P301S mice, rescuing synapse density. Thus, inhibiting complement-mediated synapse removal by microglia could be a potential therapeutic target for Tau-associated neurodegeneration.

limit search to this category
Advanced Search

Advanced Search

close
  • Publications
  • Application Notes
  • Posters
  • Workshops
  • Videos & Webinars
  • Articles
Search

Browse by Category

  • Application
    • Diagnostic and Imaging
    • Genetic Medicine
    • Hematology
    • Metabolic Disorders
    • Neuroscience
    • Oncology
    • Skeletal Disorders
    • Targeted Drug Delivery
    • Vaccines
    • Other Applications
    • Cell therapy
  • Formulation
    • Liposomes
    • Nucleic Acid Lipid Nanoparticles
    • Polymeric Nanoparticles
    • Other Formulations
  • Payload
    • DNA
    • microRNA
    • mRNA
    • siRNA
    • Small Molecule Drugs
    • Other Payloads


related content

Publication - Summary

Dec 19, 2017
Cell Reports

Systemic Messenger RNA Therapy as a Treatment for Methylmalonic Acidemia

D. An, J.L. Schneller, A. Frassetto, S. Liang, X. Zhu, J.S. Park, M. Theisen, S.J. Hong, J. Zhou J, R. Rajendran, B. Levy, R. Howell, G. Besin, V. Presnyak, S. Sabnis, K.E. Murphy-Benenato, E.S. Kumarasinghe, T. Salerno and P.G.V. Martini PGV

mRNA Metabolic Disorders Nucleic Acid Lipid Nanoparticles

Inborn errors of metabolism (IEMs) can be relatively straight forward to screen for and diagnose; these disorders however, have currently very limited options for treatment. Methylmalonic acidemia (MMA), is an IEM caused by complete or partial defi...

Read More


Publication - Summary

Sep 24, 2017
Nano Letters

Boosting Intracellular Delivery of Lipid Nanoparticle-Encapsulated mRNA

A. Patel, N. Ashwanikumar, E. Robinson, A. DuRoss, C. Sun, K.E. Murphy-Benenato, C. Mihai, Ö. Almarsson and G. Sahay

mRNA Nucleic Acid Lipid Nanoparticles Genetic Medicine

Gene delivery for the purpose of protein expression has been traditionally performed by electroporation or viral transduction of plasmid DNA. Plasmid delivery has numerous challenges as they could potentially integrate into host genome and require ...

Read More


Sign Up and Stay Informed
Sign up today to automatically receive new Cytiva, formerly Precision NanoSystems application notes, conference posters, relevant science publications, and webinar invites.
Sign Up